How Did the Updated 2019 European Society of Cardiology/European Atherosclerosis Society Risk Categorization for Patients with Diabetes Affect the Risk Perception and Lipid Goals? A Simulated Analysis of Real-life Data from EPHESUS Study

Autor: Özcan Başaran, Volkan Doğan, Kadir Uğur Mert, Bülent Özlek, Eda Özlek, Oğuzhan Çelik, Cem Çil, İbrahim Halil Özdemir, İbrahim Rencüzoğulları, Fatma Özpamuk Karadeniz, Mehmet Tekinalp, Lütfü Aşkın, Selami Demirelli, Erkan Gencer, Lütfü Bekar, Müjdat Aktaş, Mübariz Murat Resulzade, Macit Kalçık, Gökhan Aksan, Göksel Çinier, Kadriye Halil Akay, Nihat Pekel, Gurbet Özge Mert, Utku Şenol, Vahit Demir, Sinan İnci, Emir Derviş, Murat Biteker, Meral Kayıkçıoğlu
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Anatolian Journal of Cardiology, Vol 27, Iss 2, Pp 78-87 (2023)
Druh dokumentu: article
ISSN: 2149-2271
DOI: 10.14744/AnatolJCardiol.2022.2012
Popis: Background: The recent 2019 European Society of Cardiology/European Atherosclerosis Society practice guidelines introduced a new risk categorization for patients with diabetes. We aimed to compare the implications of the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines with regard to the lipid-lowering treatment use, low-density lipoprotein cholesterol goal attainment rates, and the estimated proportion of patients who would be at goal in an ideal setting. Methods: Patients with diabetes were classified into 4 risk categories according to 2019 European Society of Cardiology/European Atherosclerosis Society dyslipidemia guidelines from the database of EPHESUS (cross-sectional, observational, countrywide registry of cardiology outpatient clinics) study. The use of lipid-lowering treatment and low-density lipoprotein cholesterol goal attainment rates were then compared according to previous and new guidelines. Results: This analysis included a total of 873 diabetic adults. Half of the study population (53.8%) were on lipid-lowering treatment and almost one-fifth (19.1%) were on high-intensity statins. While low-density lipoprotein cholesterol goal was achieved in 19.5% and 7.5% of patients, 87.4% and 69.6% would be on target if their lipid-lowering treatment was intensified according to 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society lipid guidelines, respectively. The new target
Databáze: Directory of Open Access Journals